Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Indacaterol 27.5 mcg;   Drug: Indacaterol 37.5;   Drug: Indacaterol 55 mcg;   Drug: Indacaterol 75 mcg;   Drug: Indacaterol 150 mcg;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting – verified October 2013

View full post on ClinicalTrials.gov: asthma | received in the last 14 days